{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T20:47:36Z","timestamp":1761252456340},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Paricalcitol is a less hypercalcemic vitamin D analog that has been shown to suppress secondary hyperparathyroidism and to prevent the associated histomorphometric changes in bone. In this study, we show that paricalcitol also ameliorates the renal insufficiency-induced loss of bone mineral and the mechanical competence of bone.<\/jats:p>\n               <jats:p>Introduction: Renal bone disease is a common consequence of chronic renal insufficiency and the associated secondary hyperparathyroidism (SH). Paricalcitol [19-nor-1,25(OH)2D2] has been shown to ameliorate SH and prevent renal failure\u2013induced histomorphometric changes in bone with minimal calcemic and phosphatemic activity. However, information about its efficacy on restoration of bone structural strength is lacking. In this study, we explored the effects of paricalcitol treatment on bone structure and strength in a model of advanced renal disease.<\/jats:p>\n               <jats:p>Materials and Methods: Forty-five 8-week-old rats were randomly assigned to either surgical 5\/6 nephrectomy (NTX) or Sham-operation. After a 15-week postoperative disease progression period, the NTX rats were further allocated to uremic control (NTX) and treatment (NTX + paricalcitol) groups, the latter of which received paricalcitol for the subsequent 12 weeks. After 27 weeks, the animals were killed, plasma samples were collected, and both femora were excised for comprehensive analysis of the femoral neck and midshaft (pQCT and biomechanical testing).<\/jats:p>\n               <jats:p>Results: High mortality that exceeded 30% was observed in both NTX groups. NTX induced over a 13-fold increase in plasma PTH, whereas this increase was only 5-fold after paricalcitol treatment. At the femoral neck, NTX was associated with an 8.1% decrease (p &amp;lt; 0.05) in vBMD and a 16% decrease in breaking load (p &amp;lt; 0.05) compared with the Sham group, whereas paricalcitol treatment completely prevented these changes. At the femoral midshaft, the NTX resulted in a 6.6% decrease in cortical BMD (p &amp;lt; 0.01 versus Sham), and this change was also prevented by paricalcitol.<\/jats:p>\n               <jats:p>Conclusions: Paricalcitol administration prevented renal insufficiency-associated decreases in BMD in the femoral neck and the femoral midshaft and restored bone strength in the femoral neck. Therefore, paricalcitol can efficiently ameliorate renal insufficiency-induced loss of bone mineral and mechanical competence of bone.<\/jats:p>","DOI":"10.1359\/jbmr.060114","type":"journal-article","created":{"date-parts":[[2006,5,30]],"date-time":"2006-05-30T09:19:38Z","timestamp":1148980778000},"page":"745-751","source":"Crossref","is-referenced-by-count":17,"title":["Paricalcitol [19-Nor-1,25-(OH)2D2] in the Treatment of Experimental Renal Bone Disease"],"prefix":"10.1093","volume":"21","author":[{"given":"Jarkko","family":"Jokihaara","sequence":"first","affiliation":[{"name":"Department of Pharmacological Sciences, University of Tampere, Tampere, Finland"},{"name":"Department of Surgery, Tampere University Hospital, Tampere, Finland"},{"name":"Medical School and the Institute of Medical Technology, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"P\u00f6rsti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Tampere, Tampere, Finland"},{"name":"Department of Internal Medicine, Tampere University Hospital, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilari","family":"Pajam\u00e4ki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tampere University Hospital, Tampere, Finland"},{"name":"Medical School and the Institute of Medical Technology, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuomo","family":"Vuohelainen","sequence":"additional","affiliation":[{"name":"Medical School and the Institute of Medical Technology, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasi","family":"Jolma","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland"},{"name":"Department of Pharmacological Sciences, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peeter","family":"K\u00f6\u00f6bi","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Kalliovalkama","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onni","family":"Niemel\u00e4","sequence":"additional","affiliation":[{"name":"Etel\u00e4-Pohjanmaa Central Hospital Laboratory, Department of Clinical Chemistry, Sein\u00e4joki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Kannus","sequence":"additional","affiliation":[{"name":"Bone Research Group, UKK-Institute, Tampere, Finland"},{"name":"Department of Surgery, Tampere University Hospital, Tampere, Finland"},{"name":"Medical School and the Institute of Medical Technology, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harri","family":"Siev\u00e4nen","sequence":"additional","affiliation":[{"name":"Bone Research Group, UKK-Institute, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppo LN","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tampere University Hospital, Tampere, Finland"},{"name":"Medical School and the Institute of Medical Technology, University of Tampere, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"issue":"(5 Suppl 5)","key":"2024013019390253000_bib1","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1053\/ajkd.2001.28109","article-title":"Vitamin D analogues for the management of secondary hyperparathyroidism","volume":"38","author":"Martin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2024013019390253000_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","article-title":"Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy","volume":"46","author":"Goodman","year":"1994","journal-title":"Kidney Int"},{"key":"2024013019390253000_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2024013019390253000_bib4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","article-title":"Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney Int"},{"key":"2024013019390253000_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1359\/jbmr.1997.12.10.1539","article-title":"On our age-related bone loss: Insights from a new paradigm","volume":"12","author":"Frost","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1359\/jbmr.1997.12.10.1547","article-title":"Muscle strength, bone mass, and age-related bone loss","volume":"12","author":"Burr","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1359\/jbmr.1998.13.8.1213","article-title":"A structural approach to renal bone disease","volume":"13","author":"Parfitt","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib8","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1093\/ndt\/gfg374","article-title":"Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure","volume":"18","author":"Jolma","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2024013019390253000_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jor.1100010409","article-title":"Effects of freezing and freeze-drying on the biomechanical properties of rat bone","volume":"1","author":"Pelker","year":"1984","journal-title":"J Orthop Res"},{"key":"2024013019390253000_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/17453676608989401","article-title":"Factors affecting the determination of the physical properties of femoral cortical bone","volume":"37","author":"Sedlin","year":"1966","journal-title":"Acta Orthop Scand"},{"key":"2024013019390253000_bib11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1523-1755.2004.66006.x","article-title":"High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure","volume":"66","author":"P\u00f6rsti","year":"2004","journal-title":"Kidney Int"},{"key":"2024013019390253000_bib12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.2003.18.3.544","article-title":"The bone gain induced by exercise in puberty is not preserved through a virtually life-long deconditioning: A randomized controlled experimental study in male rats","volume":"18","author":"Pajamaki","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1359\/jbmr.1998.13.9.1475","article-title":"Randomized controlled study of effects of sudden impact loading on rat femur","volume":"13","author":"J\u00e4rvinen","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S8756-3282(98)00025-8","article-title":"Dual-energy X-ray absorptiometry in predicting mechanical characteristics of rat femur","volume":"22","author":"J\u00e4rvinen","year":"1998","journal-title":"Bone"},{"key":"2024013019390253000_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jbmr.5650090317","article-title":"Long-term exercise of young and adult female rats: Effect on femoral neck biomechanical competence and bone structure","volume":"9","author":"Sogaard","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S8756-3282(03)00100-5","article-title":"Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading","volume":"32","author":"J\u00e4rvinen","year":"2003","journal-title":"Bone"},{"key":"2024013019390253000_bib17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1359\/jbmr.2003.18.7.1292","article-title":"Femoral neck response to exercise and subsequent deconditioning in young and adult rats","volume":"18","author":"J\u00e4rvinen","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019390253000_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S8756-3282(01)00491-4","article-title":"Understanding bone strength: Size isn't everything","volume":"29","author":"van der Meulen","year":"2001","journal-title":"Bone"},{"key":"2024013019390253000_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1359\/JBMR.050211","article-title":"Revival of bone strength: The bottom line","volume":"20","author":"Jarvinen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"(2 Suppl 2)","key":"2024013019390253000_bib20","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/ajkd.1998.v32.pm9808142","article-title":"Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats","volume":"32","author":"Slatopolsky","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2024013019390253000_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2024013019390253000_bib22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2024013019390253000_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1681\/ASN.V1271468","article-title":"Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells","volume":"12","author":"Finch","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2024013019390253000_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00302075","article-title":"Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats","volume":"57","author":"Jablonski","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2024013019390253000_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"2024013019390253000_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019390253000_bib27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/01.CIR.98.13.1302","article-title":"1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide","volume":"98","author":"Jono","year":"1998","journal-title":"Circulation"},{"key":"2024013019390253000_bib28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.CIR.96.6.1755","article-title":"Active serum vitamin D levels are inversely correlated with coronary calcification","volume":"96","author":"Watson","year":"1997","journal-title":"Circulation"},{"issue":"(Suppl 4)","key":"2024013019390253000_bib29","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1097\/01.ASN.0000081668.41546.2B","article-title":"New developments in hyperphosphatemia management","volume":"14","author":"Slatopolsky","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2024013019390253000_bib30","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"issue":"(4 Suppl 3)","key":"2024013019390253000_bib31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00111-2","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.060114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/5\/745\/56479448\/5650210510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/5\/745\/56479448\/5650210510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:16Z","timestamp":1710341176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/5\/745-751\/7593283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.060114","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,5,1]]},"published":{"date-parts":[[2006,5,1]]}}}